A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development

Cell Biology and Toxicology

Volumn 19, Issue 3, 2003, Pages 161-176

  Casartelli, A ^a   Bonato, M ^a   Cristofori, P ^a   Crivellente, F ^a   Dal Negro, G ^a   Masotto, I ^a   Mutinelli, C ^c   Valko, K ^b   Bonfante, V ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NONE

Author keywords

Cationic amphiphilic drugs; Chromatographic hydrophobicity index; Flow cytometry, fluorescent probe; Monocytes; Phospholipidosis

Indexed keywords

2,3 DIDEHYDRO 3 DEOXYTHYMIDINE; 2,3 DIDEOXYCYTIDINE; 2,3 DIDEOXYINOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIMALARIAL AGENT; AZITHROMYCIN; CATION; CHLOROQUINE; CITALOPRAM; DIDANOSINE; ERYTHROMYCIN; FENOFIBRATE; FLUORESCENT DYE; FLUOXETINE; IMIPRAMINE; LOCAL ANESTHETIC AGENT; MACROLIDE; MAPROTILINE; NILE RED; OXAZINE DERIVATIVE; PARACETAMOL; PHOSPHOLIPID; PROCAINE; QUINIDINE; SURFACTANT; TELITHROMYCIN; TETRACYCLINE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; XENOBIOTIC AGENT; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CELL CULTURE; CELL DAMAGE; CELL LINE; CELL STRAIN U937; CELL SURVIVAL; CHROMATOGRAPHY; CLASSIFICATION; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IATROGENIC DISEASE; LIPIDOSIS; METABOLISM; METHODOLOGY; MONOCYTE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STAINING;

CATIONS; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; HUMANS; LIPIDOSES; OXAZINES; PHOSPHOLIPIDS; RECOVERY OF FUNCTION; STAINING AND LABELING; SURFACE-ACTIVE AGENTS; U937 CELLS; XENOBIOTICS;

EID: 0043028534     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024778329320     Document Type: Article

References (42)

1. Agarwal RP, Olivero OA. Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3′-azido-2′,3′-dideoxythymidine. Mutat Res. 1997;390(3): 223-31.
2. Bambeke VB, Montenez JP, Piret J, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. Interaction of the macrolide azithromycin with phospholipids. 1. Inhibition of lysosomal phospholipase A1 activity. Eur J Pharmacol. 1996;314:203-14.
3. Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci. 1997;149:19-25.
4. Brown WJ, Sullivan TR, Greenspan P. Nile red staining of lysosomal phospholipid inclusions. Histochemistry. 1992; 97:349-54.
5. Colombo MI, Bertini F. Properties of binding sites for chloroquine in liver lysosomal membranes. J Cell Physiol. 1988; 137:598-602.
6. Cotran RS, Kumar V, Robbins SL. Genetic disorders. In: Cotrans RS, Kumar V, Robbins SL, eds. Robbins pathologic bases of disease, 5th ed. Philadelphia: WB Saunders; 1994:138-43.
7. Drew R, Siddik ZH, Mimnaugh EG, Gram TE. Species and dose differences in the accumulation of imipramine by mammalian lungs. Drug Metab Dispos. 1981;9:322-6.
8. Gerschenson M, Nguyen VT, St Claire MC et al. Chronic stavudine exposure induced hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. J Hum Virol. 2001;4(6):335-42.
9. Greenspan P, Mayer EP, Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol. 1985;100:965-73.
10. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 1997;25(1):53-60.
11. Hansson AL, Xia Z, Berglund C, Bergstrand A, DePierre JV, Nassberger L. Reduced cell survival and morphological alterations induced by three tricyclic antidepressants in human peripheral monocytes and lymphocytes and in cell lines derived from these cell types. Toxicol In Vitro. 1997;11: 21-31.
12. Harris P, Ralph P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol. 1985;37:407-22.
13. Honegger UE, Zuhelke RD, Scuntaro I, Schaefer MHA, Toplak H, Wiesmann UN. Biochem Pharmacol. 1993;45(2):349-56.
14. Horn JW, Jensen CB, White SL, et al. In vitro and in vivo ultrastructural changes induced by macrolide antibiotic LY281389. Fundam Appl Toxicol. 1996;32:205-16.
15. Jaeschke H, Gores GJ, Cederbaum Al, Hinson JA, Pessayre D, Lemaster JJ. Mechanisms of hepatotoxicity. Tox Sci. 2002; 65:166-76.
16. Jagel M, Lüllmann-Rauch R. Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics. Arch Toxicol. 1984;55:229-32.
17. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 2001;276(44):40847-57.
18. Joshi UM, Kodavanti PR, Coudert B, Dwyer TM, Mehendale HM. Types of interactions of amphiphilic drugs with phospholipid vescicles. J Pharmacol Exp Ther. 1988;246(1): 150-7.
19. Joshi UM, Rao P, Kodavanti S, Lockard VG, Mehendale HM. Fluorescence studies of binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim Biophys Acta 1989;1004(3):309-20.
20. Kacew S, Nabraitz R, Ruddik JA, Villeneuve DC. Role of drug metabolism in protection against chloropentermine-induced pulmonary phospholipidosis in adult rat. Exp Mol Pathol. 1981;35:98-107.
21. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22(6):685-708.
22. Kodavanti UP, Mehendale HM. Cationic amphiphilic drugs and phospholipid storage disorder. Pharm Rev. 1990;42:327-53.
23. Lüllmann-Rauch R. Drug-induced lysosomal storage disorders. Front Biol. 1979;48:49-130.
24. Lüllmann-Rauch R., Nassberger L. Citalopram-induced generalized lipidosis in rats. Acta Pharmacol Toxicol. 1983;52(3):161-7.
25. Lüllmann H, Lüllmann-Rauch R, Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochem Pharmacol. 1978;27:1103-8.
26. Milosavljevic D, Griglio S, Le Naour G, Chapman MJ. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis. 2001;155(1):251-60.
27. Montenez JP, Van Bambeke F, Piret J, Brasseur R, Tulkens PM, Mingeot-Leclerq MP. Interactions of macrolide antibiotics (erythromycin A, roxithromycin, erythromycylamine [dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol Appl Pharmacol. 1999;156: 129-40.
28. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues. Drug Saf. 2000;23(6):467-81.
29. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol. 1999;15(6):367-73.
30. Reasor MJ. A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol Appl Pharmacol. 1989;97:47-56.
31. Robinson RL, Visscher GE, Roberts SA, Engstrom RG, Hartman HA, Ballard FH. Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug. Toxicol Pathol. 1985;13(4):335-48.
32. Schneider P, Korolenko TA, Busch U. A review of drug-induced lysosomal disorders of the liver in man and laboratory animals. Microsc Res Tech. 1997;36:253-75.
33. Schreier S, Malheiros SVP, De Paula E. Surface active drugs: self-association and interaction with membranes and surfactants. Physicochemical and biological aspects. Biochim Biophys Acta 2000;1508:210-34.
34. Staubli W, Schweizer W, Suter J. Some properties of myeloid bodies induced in rat liver by an antidepressant drug (maprotiline). Exp Mol Pathol. 1978;28(2):177-95.
35. Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int J Cancer. 1976;17:565-77.
36. Tanaka H, Furusato M, Takasaki S, Watanabe M, Hattori Y. Morphological and biochemical alteration in the rat liver induced by maprotiline. Acta Pathol Japon. 1975;25(4):413-37.
37. Tang W, Borel AG, Fujimiya T, Abbott FS. Fluorinated analogues as a mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem Res Toxicol. 1995;8(5):671-82.
38. Valko K, Du CM, Bevan CD, Reynolds DP, Abraham MH. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. J Pharm Sci. 2000;89(8): 1085-96.
39. Waters E, Wang JH, Redmond HP, Wu QD, Kay E, Bouchier-Hayes D. Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. Am J Physiol Gastrointest Liver Physiol. 2001;280(6):G1274-9.
40. Wladyslawa AD, Wojcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol. 1997;80:62-8.
41. Xia Z, Appelkvist EL, DePierre JW, Nässberger L. Tricyclic antidepressant-induced lipidosis in human peripheral monocytes in vitro, as well as in a monocyte-derived cell line, as monitored by spectrofluorimetry and flow cytometry after staining with Nile red. Biochem Pharmacology 1997; 53:1521-32.
42. Xia Z, Ying G, Hansson AL, et al. Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog Neurobiol. 2000;60(6):501-12.